Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALPG | P10696 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25187586 | 0.85 | PARP1 (0.34) | PARP1HPGDCYP1A2CYP2D6ALPG | |
| SCHEMBL25607486 | 0.75 | PARP1 (0.35) | PARP1HPGDCYP1A2CYP2D6ALPG | |
| SCHEMBL30235082 | 0.74 | PARP1 (0.33) | PARP1HPGDCYP1A2CYP2D6ALPG | |
| SCHEMBL25187590 | 0.74 | PARP1 (0.33) | PARP1HPGDCYP1A2CYP2D6ALPG | |
| SCHEMBL25093456 | 0.74 | PARP1 (0.49) | PARP1CYP1A2CYP2D6ALPGCYP2C19 | |
| SCHEMBL30019173 | 0.74 | PARP1 (0.49) | PARP1CYP1A2CYP2D6ALPGCYP2C19 | |
| SCHEMBL30618934 | 0.72 | — | — | |
| SCHEMBL30618932 | 0.72 | HPGD (0.32) | HPGDCYP1A2CYP2D6ALPGCYP2C19 | |
| SCHEMBL8478795 | 0.71 | HPGD (0.44) | PARP1HPGDCYP1A2CYP2D6ALPG | |
| SCHEMBL25315984 | 0.70 | NQO2 (0.33) | HPGDCYP1A2CYP2D6ALPGCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159525-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | XINTHERA, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159525-A1 | AZETIDINE AND PYRROLIDINE PARP1 INHIBITORS AND USES THEREOF | PARP1, PARP11, PARP12 | PARP1 1/4885HPGD 252/4885CYP1A2 2630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.